Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Shares Surge 30 Percent as Revenue Climbs 23 Percent and Firm Swings to Profit

NEW YORK (GenomeWeb News) — Luminex today said fourth-quarter revenue increased 23 percent as R&D spending rose 43 percent as it swung to a profit.
 
News of the earnings caused shares in the company to surge 30 percent, or $3.76, to $16.49 in early-afternoon trading today.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $14.2 million from $11.6 million year over year.
 
R&D spending increased to $2.3 million from $1.6 million year over year.
 
The company said it swung to a profit of $599,000 from a loss of $1.3 million in the year-ago period.
 
Luminex said it had around $27.4 million in cash and equivalents and $11 million in short-term investments as of Dec. 31, 2006.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.